Assessing the value of AI in healthcare

Tim Govers, CEO of Medip Analytics, co-authored a commentary in European Radiology with Robin Vermeulen and Kicky van Leeuwen on the value assessment of AI products in healthcare.

Evaluation throughout development

AI products can change as they are developed and updated. The evidence available also changes over time. The commentary discusses a flexible approach to health technology assessment that can inform development rather than only evaluate the finished product.

Early assessment can help teams explore potential value and identify evidence gaps. Conclusions remain conditional on the evidence and assumptions available at that stage.

Connect performance with consequences

For an adoption decision, a performance measure needs to be connected with the clinical pathway. Which decisions change after an AI result? What does that mean for patients, resource use and costs in the intended setting?

Read the commentary in European Radiology.